Can the HPV vaccine cause injury and/or death?
IMPORTANT NOTE: Corvelva invites you to get in-depth information by reading all the sections and links, as well as the manufacturer's product leaflets and technical data sheets, and to speak with one or more trusted professionals before deciding to vaccinate yourself or your child. This information is for informational purposes only and is not intended as medical advice.
The following article tries to shed light on the vast world of adverse reactions, with a specific look at the one against Papillomavirus, but we urge you to read all the focuses reported below to understand the other related issues, such as the problem of multiple vaccines, the hypersensitivity to one or more vaccine compounds, the SIDS problem and that of adjuvants. Most of the vaccines on the market are produced, for commercial purposes, in often multiple formulations and this makes the topic of vaccine damage much broader.
The problem of multiple vaccines (click to open)
The aluminum problem (click to open)
The most commonly reported side effects of HPV vaccination include: injection site pain, swelling, and redness, nausea, headache, fever, fatigue, and muscle or joint pain. Fainting - termed a syncopal episode - following HPV vaccination has been reported frequently, and as a result, vaccine recipients are advised to remain seated or lie down to prevent syncope and potential injury that can result from a fall.(1)
Some of the adverse events reported by manufacturers during pre-licensing clinical trials include:
Gardasil - injection site pain, swelling, redness and bruising, fever, headache, nausea, dizziness, syncope, sometimes in conjunction with seizure-like activity, anaphylaxis, diarrhea, vomiting, cough, upper respiratory tract infection, nasal congestion , insomnia, malaise, oropharyngeal pain, nasopharyngitis, upper abdominal pain, gastroenteritis, appendicitis, pelvic inflammatory disease, urinary tract infection, pneumonia, pulmonary embolism, pyelonephritis, bronchospasm, and death.(2)
Cervarix - injection site pain, redness, bruising and swelling, syncope, fatigue, headache, gastrointestinal symptoms, rash, fever, arthralgia, myalgia, hives, urinary tract infection, back pain, dysmenorrhea, nasopharyngitis, influenza, vaginal infection , pharyngitis, chlamydial infection, arthritis, rheumatoid arthritis, celiac disease, diabetes mellitus, erythema nodosum, inflammatory bowel disease, hyperthyroidism, hypothyroidism, multiple sclerosis, transverse myelitis, systemic lupus erythematosus, thrombocytopenia, vasculitis, optic neuritis, vitiligo, and death.(3)
Gardasil 9 - injection site pain, swelling, redness, and bruising, syncope, fever, headache, nausea, dizziness, fatigue, diarrhea, upper respiratory tract infection, upper abdominal pain, oropharyngeal pain, myalgia, asthma attack, anaphylaxis, and death .(4)
Post-marketing adverse events reported for Gardasil 9 include: pulmonary embolism, idiopathic thrombocytopenic purpura, lymphadenopathy, autoimmune haemolytic anemia, pancreatitis, asthenia, chills, fatigue, malaise, bronchospasm, urticaria, anaphylaxis, acute disseminated encephalomyelitis, dizziness, transverse myelitis, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizure, syncope (including syncope associated with other seizure-like activities and tonic-clonic movements) sometimes with fall injury, deep vein thrombosis, cellulitis, myalgia, arthralgia and death.
Over the past decade, there have been numerous studies and reports linking HPV vaccination to chronic disease in children and young adults. These include anaphylaxis,(5) lupus,(6-7) erythema multiforme,(8) acute disseminated encephalomyelitis,(9-10-11) transverse myelitis,(12) amyotrophic lateral sclerosis (ALS),(13) demyelination of the central nervous system,(14-15) multiple sclerosis,(16) including pediatric multiple sclerosis,(17) Guillain-Barre syndrome,(18-19) pancreatitis,(20-21) inflammatory bowel syndrome,(22) brachial plexus neuritis,(23) brachial neuritis,(24) optic neuritis,(25) neuromyelitis optica,(26) opsoclonus myoclonus,(27) vanishing white point syndrome,(28-29) acute cerebellar ataxia,(30) autoimmune hepatitis,(31) autoimmune neuromyotonia,(32) vasculitis,(33) thrombocytopenic purpura,(34) immune thrombocytopenic purpura,(35) postural orthostatic tachycardia syndrome (POTS),(36-37-38) complex regional pain syndrome (CRPS),(39) chronic fatigue syndrome (CFS),(40) and peripheral sympathetic nerve dysfunction.(41) A published questionnaire(42) on people who received HPV vaccination and looked at a combination of chronic diseases, including POTS, CRPS and fibromyalgia, found that 93% of people reporting symptoms related to these conditions were still unable to work or attend school four years later the vaccination. Additionally, several studies have linked HPV vaccination to primary ovarian failure, resulting in reduced fertility(43-44-45-46). A 2018 study found lower pregnancy rates in women who had received the HPV vaccination.(47)
Adverse events following HPV vaccination have also been linked to a relatively new medical condition called Adjuvant-Induced Autoimmune/Inflammatory Syndrome (ASIA).(48) In 2011, Dr. Yehuda Shoenfeld, founder and director of the Zabludowicz Center for Autoimmune Diseases in Israel, has released a paper associating four medical conditions - Gulf War Syndrome (GWS), macrophagic myofasciitis (MMF) syndrome (a syndrome previously related to use of aluminum adjuvants), siliconeosis (a condition related to silicone breast implants) and post-vaccination phenomena (chronic illness following vaccination) to previous exposure to adjuvants.
Dr. Shoenfeld noted that patients with these conditions had very similar clinical symptoms. Since then, published studies have linked the aluminum adjuvant in the HPV vaccine to several chronic health conditions, including postural tachycardia syndrome (POTS),(49) primary ovarian insufficiency (POF),(50) chronic epipharyngitis,(51) pseudo-neurological syndrome,(52) and severe somatoform and dysautonomic syndromes.(53) An epidemiological study of data collected by the Federal Vaccine Adverse Event Reporting System (VAERS) estimated that 3,6 per 100.000 doses of HPV vaccination resulted in symptoms consistent with a diagnosis of ASIA.(54)
A study on the effects of HPV vaccination found that both HPV antigens and aluminum adjuvant appear to have the ability to trigger autoimmune reactions and neuroinflammation in female mice, resulting in changes in behavioral patterns.(55)
Studies linking HPV vaccination to sudden death in previously healthy women have also been published. A study published in 2012 of two deaths following HPV vaccination concluded that the HPV-16L1 antigens present in HPV vaccines have the potential to cause fatal autoimmune vascular disease.(56) Also in 2012, Sin Hang Lee, a researcher and licensed pathologist, published a case study involving the sudden and unexplained death of a young woman six months after completing a three-dose series of Gardasil. Dr. Lee found HPV-16 gene DNA in blood and spleen similar to the HPV-16 gene DNA fragments contained in Gardasil. The DNA of the HPV-16 LI gene was bound to the same aluminum adjuvant present in the vaccine, which protected it from degradation. It is not yet known whether these HPV DNA fragments played a role in the girl's death.
A 2017 article published in Drug Safety looked at the safety issues associated with HPV vaccination.(57) Data reported in the adverse reaction reporting systems of several countries were analyzed and a relatively large number of reports of headache, dizziness, fatigue and syncope associated with prolonged hospitalization or debilitation were found. While some reports reported Postural Orthostatic Tachycardia Syndrome (POTS), Complex Regional Pain Syndrome (CRPS), or Chronic Fatigue Syndrome (CFS) as diagnoses, the vast majority of reports reported no diagnoses. This study also found significantly more events involving a combination of dizziness and headache with syncope or fatigue following HPV vaccination than adverse reactions from other vaccines. It was also noted that these symptom combinations were first reported in the countries that first approved and recommended HPV vaccination, and that the reported symptoms persisted globally.
Because of these findings, others have questioned whether current drug and vaccine safety monitoring tools can adequately detect and respond to signs that there is a serious problem with a currently marketed product.(58) Additionally, a 2018 study found that only about half of the available clinical trials of HPV vaccines had been completed before the vaccines were approved by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA).(59) The study also found that drugmakers only published the results of about two-thirds of HPV clinical trials, leaving the study authors wondering whether drugmakers were selectively choosing which clinical data to publish.
In December 2017, Slate Magazine ran a cover story about the pre-approval clinical trials of the Gardasil vaccine.(60) This investigative report determined that Merck's pre-approval safety studies "used a convoluted method that made objective assessment and reporting of potential side effects impossible during all but a few weeks of the years-long trial."(61) The article noted that Merck's clinical investigators were allowed to use personal judgment in reporting medical problems as adverse events, essentially allowing the study investigators to decide which symptoms, if any, could be related to the vaccination. The study investigators were also allowed to list new post-vaccination health problems as medical history, not adverse events, and to limit safety follow-up to 14 days after each of the three Gardasil vaccination doses. Slate's investigation identified several women involved in pre-licensure trials of Gardasil who reported post-vaccination chronic illnesses to the study investigators, but their symptoms were never reported by Merck.
In April 2018, the Indian Journal of Medical Ethics published a report suggesting that rising cervical cancer rates in Sweden may be associated with HPV vaccination. Concerned that he might be targeted for questioning the safety or efficacy of a vaccine, the study author chose to publish under an assumed name without first contacting the journal. Initially, the magazine decided to allow publication of the article despite the deception, after determining that the author had the necessary credentials and that he faced a credible threat of harm, stating that "the issues raised are important and discussion of them is in the public interest."(62) However, two weeks later, after receiving "valuable advice from the journal's editorial board and others," the article was retracted.(63) The journal, however, said it "hoped that the possibility of possible harm from vaccinating women previously exposed to HPV would be carefully explored in future studies."(64) Data from Gardasil's pre-approval clinical trials had previously demonstrated an increased incidence of grade 2 and 3 cervical intraepithelial neoplasia (CIN) in women previously infected with the particular vaccine target strain.(65)
According to US federal VAERS data, as of January 31, 2023, 618 deaths have been reported following HPV vaccination.(66) In Italy it is impossible to know this data.
References (click to open)
- CDC. Human Papillomavirus (HPV) Vaccine Safety. Jan. 30, 2018
- FDA. Gardasil – Product insert. Apr. 24, 2015.
- FDA. Cervarix – Product insert. Apr. 25, 2016.
- FDA. Gardasil 9 – Product insert. Feb. 9, 2018.
- Brotherton JML, Gold MS. et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008 Sep 9; 179(6): 525–533.
- Soldevilla HF, Briones SF, Navarre SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012 Feb;21(2):158-61
- Gatto M, Agmon-Levin N. et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. (2013) 32:1301.
- Katoulis AC, Liakou A. et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010; 220: 60-2.
- Sekiguchi K, Yasui N. et al. Two cases of acute disseminated encephalomyelitis following vaccination against human papilloma virus. Internal Med. 2016 Nov 1; 55(21): 3181–3184 .
- Yoneda M. Acute Disseminated Encephalomyelitis Following Immunization with Human Papillomavirus Vaccines. Intern Med. 2016 Nov 1; 55(21): 3077–3078 .
- Wildemann B, Jarius S. et al. ACUTE DISSEMINATED ENCEPHALOMYELITIS FOLLOWING VACCINATION AGAINST HUMAN PAPILLOMA VIRUS. neurology. Jun.16, 2009; 72 (24).
- Fernandez-Fournier M, Diaz de Teran J. et al. Early cervical myelitis after human papilloma virus vaccination. Neurol Neuroimmunol Neuroinflamm. 2014 Sep 11;1(3):e31
- Laino C. 2 ALS Cases May Be Linked to Gardasil Vaccine. WebMD. Oct. 16, 2009
- Chang J, Campagnolo D. et al. Demyelingating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1296-8.
- Álvarez-Soria MJ, Hernández-González A, et al. Demyelinating disease and vaccination of the human papillomavirus. Rev. Neurol. 2011 Apr 16; 52 (8): 472-6.
- Sutton I, Lahoria R. et al. CNS demyelination and quadrivalent HPV vaccination. Mult scler. 2009 Jan;15(1):116-9.
- Hu Y, Tornes L, Lopez-Alberola R. Two Cases of Pediatric Multiple Sclerosis after Human Papillomavirus Vaccination (P4.353) neurology. Apr. 10, 2018; 90 (15 Supplements)
- Souayah N, Michas-Martin PA. et al. Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine. 2011 Jan 29; 29 (5): 886-9.
- Miranda S, Chaignot C. et al. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France. Vaccine. 2017 Aug 24; 35 (36): 4761-4768.
- Das A, Chang D. et al. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008 Aug 4;189(3):178.
- Bizjak M, Bruck O. et al. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunol Res. 2017 Feb;65(1):164-167.
- Miranda S, Chaignot C. et al. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France. Vaccine. 2017 Aug 24; 35 (36): 4761-4768.
- Debeer P, De Munter P. et al. Brachial plexus neuritis following HPV vaccination. Vaccine. 2008 Aug 18; 26 (35): 4417-9.
- Taras JS, King JJ, et al. Brachial neuritis following quadrivalent human papilloma virus (HPV) vaccination. Hand (NY). 2011 Dec; 6(4): 454–456.
- DiMario FJ, Jr, Hajjar M. et al. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol. 2010 Mar;25(3):321-7.
- Menge T, Cree B. et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012 Jul 17;79(3):285-7.
- McCarthy JE, Filiano J. Opsoclonus myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord. 2009 Dec;15(10):792-4.
- Ogino K, Kishi S, Yoshimura N. Multiple Evanescent White Dot Syndrome after Human Papillomavirus Vaccination. Case Rep. Ophthalmol. 2014 Jan-Apr; 5(1): 38–43.
- Cohen SM. Multiple Evanescent White Dot Syndrome After Vaccination for Human Papilloma Virus and Meningococcus. J Pediatr Ophthalmol Strabismus. 2009 Jun 25.
- Yonee C, Toyoshima M. et al. Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report. Neuropediatrics 2013; 44: 265-7.
- Della Corte C, Carlucci A. et al. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in an 11-year-old girl. Vaccines. 2011 Jun 24;29(29-30):4654-6.
- Cerami C, Corbo M. et al. Autoimmune neuromyotonia following human papilloma virus vaccination. Muscle Nerve. Mar 2013;47(3):466–7.
- Melo Gomes S, Glover M. et al. Vasculitis following HPV immunization. Rheumatology (Oxford). 2013 Mar;52(3):581-2.
- Pugnet G, Ysebaert L. et al. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine. 2009 Jun 8;27(28):3690.
- Bizjak M, Bruck O. et al. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. 2016 Apr;53 Suppl 1:S48-50.
- Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur. J. Neurol. 2014 21:135-139.
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Brinth LS, Pors K. et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015 May 21; 33 (22): 2602-5.
- Richards S, Chalkiadis G. et al. Complex regional pain syndrome following immunization. Arch Dis Child. 2012 Oct;97(10):913-5
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Kinoshita T, Abe RT. et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53(19):2185-200.
- Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P. et al. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015 Nov;34(11):1981-3.
- Little D, Ward HR. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep. Sep. 30, 2012.
- Colafrancesco S, Perricone C. et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct;70(4):309-16
- Little DT, Ward HR. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact Case Rep. 2014 Oct 28;2(4):2324709614556129.
- Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015 Aug;27(4):265-70.
- DeLong, G. A lowered probability of pregnancy in females in the USA aged 25–29 who received a human papillomavirus vaccine injection. J Toxicol Environ Health A. 2018;81(14):661-674.
- Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmune. 2011 Feb;36(1):4-8
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Colafrancesco S, Perricone C. et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct;70(4):309-16
- Hotta O, Tanaka A. et al. Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA). Immunol Res. 2017 Feb;65(1):66-71.
- Poddighe D, Castelli L. et al. A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res. 2014;60(2–3):236–246.
- Palmieri B, Poddighe D. et al. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017; 65(1): 106–116.
- Pellegrino P, Perrone V. et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015 Feb;61(1-2):90-6.
- Inbar R, Weiss R. et al. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017 Feb;65(1):136-149
- Tomljenovic L, Shaw CA. Death after Quadrivalent Human Papillomavirus (HPV) Vaccination: Causal or Coincidental? Pharmaceutical Regulatory Affairs: Open Access 2012,S12:001
- Chandler RE, Juhlin K. et al. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. Drug Saf. 2017; 40(1): 81–90.
- Chandler RE. Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient? Drug Saf. 2017; 40(12): 1167–1170.
- Jørgensen L, Gøtzsche PC, Jefferson T. et al. Index of the human papillomavirus (HPV) vaccine industry clinical study programs and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. System Rev. 2018; 7:8.
- Joelving F. What the Gardasil Testing May Have Missed. Slate. Dec 17, 2017.
- Ibid
- EDITORIAL NOTE Statement on Corrections. Indian J Med Ethics. May 9, 2018.
- Andersson L. Comment - RETRACTED: Increased incidence of cervical cancer in Sweden: Possible link with HPV vaccination. Indian J Med Ethics. May 26, 2018.
- Ibid
- FDA Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee Meeting. May 18, 2006.
- CDC. Human Papillomavirus (HPV) Vaccine Safety. Jan. 30, 2018
This article is summarized and translated by National Vaccine Information Center.